ATAI AtaiBeckley (ATAI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0002081043
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
167
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $275.8K priced
What the filings say about ATAI
Insiders, 180 days
-$938.0K net sold
3 sellers · 0% of sales under a 10b5-1 plan
AtaiBeckley insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AtaiBeckley Inc. insiders sold a net $938.0K of stock across 36 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 100,000 shares held after it.
- 2 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HERSHBERG ROBERT sold about $496.0K of ATAI on Jul 7, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- 2 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Kochendoerfer Gerd sold about $250.0K of ATAI on Jun 26, 2026; 2 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Apr 20, 2026.
- The trade is 504.7% of the 8,437 shares held after it.
- 2 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Craig Kevin James sold about $192.0K of ATAI on Jun 25, 2026; 2 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 20, 2026.
- The trade is 504.7% of the 8,437 shares held after it.
- No other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Craig Kevin James sold about $212.9K of ATAI on Apr 20, 2026; 167 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 21, 2025.
- The trade is 1185.3% of the 8,437 shares held after it.
- No other insider sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Craig Kevin James sold about $355.0K of ATAI on Mar 20, 2026, the largest insider sale at the company on our record; 167 funds added in the latest 13F quarter.36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$938.0K over 180 days
below 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
167 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
+1227.6% year over year
more than 97% of Pharma & Biotech
Margin
-16142.0% net margin
the lowest in Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch ATAI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+32.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ATAI: institutional holders (13F)
13F holdings, latest reported quarter
25,574,573 sh
$134.8M
14,417,442 sh
$76.0M
11,747,249 sh
$61.9M
8,287,054 sh
$43.7M
6,933,309 sh
$36.5M
Congress trades in ATAI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ATAI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ROBERT HERSHBERG
Filed 2026-07-07
$496.0K
GERD KOCHENDOERFER
Filed 2026-06-26
$229.0K
KEVIN CRAIG
Filed 2026-06-25
$355.1K
ATAI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$4.7M position · as of 2026-06-30
10.5%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$446.2K position · as of 2026-07-31
2.2%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$9.1M position · as of 2026-06-30
2.1%
PROFUND VP PHARMACEUTICALS
$237.6K position · as of 2026-06-30
2.1%
Inception Portfolio
$4.2M position · as of 2026-06-30
1.5%
Virtus Biotech Clinical Trials Etf
$569.3K position · as of 2026-07-31
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $938.0K sold by insiders over 180 days, 167 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ATAI financials
Revenue growth
+1227.6%
XBRL, annual
Net margin
-16142.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | $1.7M |
| Mar 2026 | $954.0K |
| Jun 2025 | $719.0K |
| Mar 2025 | $1.6M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | -1,909% |
| Mar 2026 | -3,122% |
| Jun 2025 | -3,857% |
| Mar 2025 | -1,700% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | -$35.3M |
| Mar 2026 | -$21.1M |
| Jun 2025 | -$14.2M |
| Mar 2025 | -$18.1M |
At each fiscal year end
Single quarter
Debt to equity
0.13x
long-term 2025-12-31 plus current 2026-06-30; equity 2026-06-30
Debt to equity ATAI
| FY Dec 2025 | 0.61x |
| FY Dec 2024 | 0.12x |
| Jun 2026 | 0.13x |
| Mar 2026 | 0.84x |
| Jun 2025 | 0.12x |
| Mar 2025 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.6B
market value at close 2026-09-11 on 2026-08-07 shares, plus long-term 2025-12-31 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | $1.8B |
| Mar 2026 | $1.4B |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing ATAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-09-11. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | |
|---|---|---|
| Revenue | $4.1M | $308.0K |
| Operating income | -$644.1M | -$102.7M |
| Net income | -$660.0M | -$149.3M |
| EPS (diluted) | -2.91 | -0.93 |
| Operating cash flow | -$102.7M | -$82.4M |
| Cash | $85.3M | $17.5M |
| Long-term debt | $0 | $14.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
ATAI Stock Sonar score 4/7 axes
Find similar shapesCompareATAI ranks highest on growth (97th percentile) and institutional and government (85th), and lowest on insider conviction (18th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ATAI filings, in plain words
Are AtaiBeckley insiders buying or selling ATAI?
In the 180 days to 2026-10-28, AtaiBeckley insiders were net sellers, a net $938.0K across purchases and sales reported on Form 4, by 3 sellers.
Read the full summary
In the 180 days to 2026-10-28, AtaiBeckley insiders were net sellers of ATAI, a net $938.0K across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
